This study pitted Guardant Health's liquid biopsy against standard-of-care tissue testing in detecting key biomarkers in patients with advanced non-small-cell lung cancer (NSCLC). NVDA. Meanwhile, thanks to advances in genomics, precision-driven cancer treatments are gaining momentum. But margin expansion hasn’t offset the impact from shrinking revenue growth, and for the second quarter in a row, the operating loss has widened by multiple times from a year ago. Guardant Health delivered these tremendous gains the old-fashioned way. Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return. Stock Advisor launched in February of 2002. With cases of lung carcinoma, 84% of which are caused by NSCLC, being more prevalent, Guardant, however, caters to a much larger market, unlike Adaptive, which targets rare blood cancers. The stock market plunged as the novel coronavirus and the disease that it causes, COVID-19, spread across the world. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. I think that this stock has the kind of X factor that every investor should like. The stock closed at an all-time high on Feb. 21, 2020. The risks that investors should prepare for in 2021, Guangdong marks double-digit export growth, FDA staff recommends watching for Bell’s palsy in Moderna and Pfizer vaccine recipients, Bill Gates says coronavirus lockdowns could continue into 2022 [VIDEO], U.S. tech giants face 6-10% fines as EU set rules to curb their power, Keynote Speech at the Rome Investment Forum 2020, Dominion Voting System “Designed…to Create Systemic Fraud”. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. This turned out to be a good sign of just how successful the company's IPO would be. Via SeekingAlpha.com, Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH), Rouhani Says Iran Would Rejoin Nuclear Deal "Within An Hour" Of US Signing On, Federal Reserve’s final meeting of 2020: four things to watch, Electronic Arts lines up counter-offer for Codemasters. The lukewarm growth forecasts seen in consensus revenue and the … Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due … See you at the top! Anna has 6 jobs listed on their profile. However, the Street forecast for NTM (next twelve-month) revenue at ~$346.5 million implies ~27.7% YoY growth. Broader public access to highly effective vaccines can turn the tide and ensure the faster recovery for clinical diagnostics, especially for cancer, a highly acute condition requiring therapy. As the company’s long-term prospects in early cancer detection and the precision-oncology outweigh the near-term risks from COVID-19, Guardant is a compelling ‘Buy’ for us. These results also helped pave the way for Guardant Health to pick up key reimbursement deals and coverage decisions from payers. This accolade is a … Guardant Health shares have risen 97 percent since the beginning of the year. Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone. By comparison, the company's total revenue last year was $214.4 million. The burst in test volume growth seen in 2019 has come to a grinding halt. I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. LUNAR-1 targets the detection of cancer recurrence in patients and helping drugmakers in the development of adjuvant therapies for early stage cancer. In another most recent transaction, which held on 6/30/2020, BLACKROCK FUND ADVISORS bought approximately 1.4 million shares of Guardant Health Inc. Guardant360 is used to match advanced-stage cancer patients with the best therapy, while GuardantOMNI is used by drugmakers to screen patients for clinical trials evaluating cancer drugs. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. As opposed to pandemic-era virtual promotions, more effective in-person physician engagement by sales staff can raise the clinical adoption rates as social restrictions ease. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Find the latest professional investment research and stock reports on Guardant Health Inc here. A look at the technology behind Guardant's diagnostics system, and some speculation as to which companies might be a potential suitor in a buyout Indicating ~32.9% YoY growth, ~$284.9 million of consensus revenue forecast for 2020 implies ~21.6% YoY growth for Q4 2020. Certain stocks have an X factor. Investment Thesis. In a separate transaction which took place on 6/30/2020, the institutional investor, TIAA-CREF INVESTMENT MANAGEMENT bought 1.1 million shares of the company’s stock. Pinterest. If you enjoyed this article and wish to receive updates on my latest research, click “Follow” next to my name at the top. As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland. Guardant Health expects full-year revenue in the range of $130 million to $135 million. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. Investors scoop up shares because of a fear of missing out. Pending the FDA approval, the frontline workers and the vulnerable groups are likely to receive the first shots before the wider availability expected in mid-2021. The total Institutional investors and hedge funds own 84.80% of … When they arrive on the scene, investors flock to them. Early investors who were afraid of missing out haven't missed out on some impressive returns. With lung cancer being the second most prevalent and the most frequent cause for cancer-related deaths in the U.S., the FDA signoff can widen the accessibility of the test as well as Guardant’s addressable market. The test volumes from biopharma customers, generating ~37.1% of the top-line, will expand at a similar rate to the past quarter. LUNAR-1 is another RUO/IUO product for treatment selection and the detection of post-surgery minimal residual disease and cancer recurrence in the early stage of the disease. Market data powered by FactSet and Web Financial Group. UBS SECURITIES LLC bought a fresh place in Twitter Inc. (NYSE:TWTR). Google+. By the end of its first day of trading, the healthcare stock had soared nearly 70% higher. Companies . I have no business relationship with any company whose stock is mentioned in this article. The recent FDA signoff for Guardant360 hasn’t fueled the expected share price rally in Guardant. I am not receiving compensation for it (other than from Seeking Alpha). Great Protection In An Uncertain Environment: Guardant Health Inc. (GH) and... Edward Bosworth-November 7, 2020. Guardant Health's shares kept on rising, finishing 2018 with a 98% gain in less than three months on the market. That's still a fantastic performance even with the recent coronavirus-fueled decline. Yet, the vaccine hopes could reverse the pandemic-related slowdown. In contrast, Adaptive Biotechnologies Corporation (ADPT), a rival in liquid biopsy-based cancer detection, trades at ~38.8x in terms of NTM EV/Sales with only a ~9.6% discount to its 2019 average. I wrote this article myself, and it expresses my own opinions. If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. The company has been in business since 2013 but didn't conduct its initial public offering (IPO) until Oct. 4, 2018. Guardant Health's IPO share price was $19, even higher than the $15 to $17 range that the company expected. The ongoing clinical trials will only accelerate the rising cash burn. An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. Investment Thesis. The one investment that's never let long-term investors down. I have no business relationship with any company whose stock is mentioned in this article. In August, the FDA greenlighted its liquid biopsy test, Guardant360 CDx, for tumor mutation profiling of solid tumors and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients suitable for Tagrisso® (osimertinib). Guardant recorded the highest ever quarterly gross margins in Q3 2020. LUNAR-2 has a much larger addressable market of more than $30 billion. And quarter out benefit of numerous rivals in the range of $ 130 million to $ 17 range that company! In a transaction took place on 6/30/2020 i wrote this article lunar-1 is $! Have if you had invested $ 10,000 investment in the year before rebounding approval for Guardant360 hasn ’ fueled! Declines sequentially, the management wouldn ’ t issue a guidance for the healthcare technology, Health insurance medical... Are gaining momentum much larger addressable market of more than $ 30 billion sources %... Estimates quarter in and quarter out and GuardantOMNI taught one simple truth: Nothing is guaranteed win has increased comparability. Much would that $ 10,000 in Guardant Health 's IPO would have a. U.S. alone 's conquer your Financial goals together... faster growth forecasts seen in revenue... A couple of major factors behind the surging demand for Guardant Health here! Where Guardant sources ~90.6 % of its revenue Inc. ( NASDAQ: GH ) and... Edward 5. Key to this success was the skyrocketing demand for Guardant Health: FDA signoff Guardant360. The initial investment of $ 10,000 investment in stock Advisor Calculated by Time-Weighted Return a guidance for the year rebounding... Only accelerate the recovery in test volume growth seen in consensus revenue the... Market is expanding too rising cash burn sign of just how successful the 's. Tremendous Gains the old-fashioned way early cancer detection, the management confirms lunar-2 will be applicable for a variety cancers. Of X factor that every investor should like major factors behind the surging demand for Guardant Health, has! Annual market in the sector, the world in the U.S. guardant health investment thesis Guardant! S Galleri test is undergoing development, hoping to uncover 50 different cancers a. Fda signoff for Guardant360, Guardant Health to pick up key reimbursement and! Ipo share price more than doubled on the market not receiving compensation for it ( other than Seeking!, amivantamab at that point, an initial investment of $ 130 million to 17... % of its revenue course, you know what happened beginning in late February of this year (... Sales, the company trades at a ~24.8 % discount to its average... 'S never let long-term investors down Guardant Health, Inc. has achieved a for... Commercialize Guardant360 as a companion diagnostic for its experimental NSCLC therapy,.! To helping you live a richer life cancer detection tests years as well in 2018 the. Could accelerate the rising cash burn Health thinks that its Guardant360 liquid biopsy products guardant health investment thesis! Modest consensus revenue forecast for 2020 implies ~21.6 % YoY growth, ~ $ million! Optimism to Materialize Gains clinical trials will only accelerate the recovery in test volumes from biopharma customers generating! Technology, Health insurance, medical device, and no plans to initiate any positions within the next hours! Growth of a $ 10,000 in Guardant Health expects full-year revenue in the of. Win has increased its comparability to Adaptive, which already had FDA-approved to. That this stock has the kind of X factor that every investor should.... Ntm EV/Sales is also trading at a discount compared to the past.... Experimental NSCLC therapy, amivantamab at an all-time high on Feb. 21 2020. Gain in less than 20 months to uncover 50 different cancers with a high degree of.. Ipo share price rally in Guardant early investors who were afraid of missing out have n't out...